- Home
- SCYX vs NRXP Comparison
SCYX vs NRXP Comparison
Compare SCYX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- NRXP
- Stock Information
- Founded
- SCYX 1999
- NRXP 2015
- Country
- SCYX United States
- NRXP United States
- Employees
- SCYX N/A
- NRXP N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SCYX Health Care
- NRXP Health Care
- Exchange
- SCYX Nasdaq
- NRXP Nasdaq
- Market Cap
- SCYX 28.5M
- NRXP 32.6M
- IPO Year
- SCYX 2014
- NRXP N/A
- Fundamental
- Price
- SCYX $0.82
- NRXP $3.21
- Analyst Decision
- SCYX
- NRXP Strong Buy
- Analyst Count
- SCYX 0
- NRXP 4
- Target Price
- SCYX N/A
- NRXP $28.50
- AVG Volume (30 Days)
- SCYX 176.2K
- NRXP 202.4K
- Earning Date
- SCYX 08-07-2025
- NRXP 08-13-2025
- Dividend Yield
- SCYX N/A
- NRXP N/A
- EPS Growth
- SCYX N/A
- NRXP N/A
- EPS
- SCYX N/A
- NRXP N/A
- Revenue
- SCYX $2,630,000.00
- NRXP N/A
- Revenue This Year
- SCYX $463.61
- NRXP N/A
- Revenue Next Year
- SCYX $310.80
- NRXP N/A
- P/E Ratio
- SCYX N/A
- NRXP N/A
- Revenue Growth
- SCYX N/A
- NRXP N/A
- 52 Week Low
- SCYX $0.66
- NRXP $1.10
- 52 Week High
- SCYX $2.29
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- SCYX 57.87
- NRXP 51.07
- Support Level
- SCYX $0.67
- NRXP $3.12
- Resistance Level
- SCYX $0.75
- NRXP $3.53
- Average True Range (ATR)
- SCYX 0.04
- NRXP 0.18
- MACD
- SCYX 0.01
- NRXP -0.05
- Stochastic Oscillator
- SCYX 93.53
- NRXP 41.82
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.